| Vanaja Nandini Alexander, MD | |
|
3708 5th St S, Arlington, VA 22204-1681 | |
| (703) 403-4672 | |
| Not Available |
| Full Name | Vanaja Nandini Alexander |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Neonatal-perinatal Medicine |
| Location | 3708 5th St S, Arlington, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538496807 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080N0001X | Pediatrics - Neonatal-perinatal Medicine | 243433 (New York) | Primary |
| Entity Name | Medical Faculty Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417990581 PECOS PAC ID: 4082528898 Enrollment ID: O20031117000341 |
News Archive
Healthnostics, Inc., a medical and biotechnology analytics company today announced the inclusion of a hospitalist (hospital employed physicians, physician assistants and nurse practitioners) focus for the MedGuardian patient clinical monitoring and risk management system.
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
Advertising on the health care debate, more than $100 million of it spent so far, is offering little understanding on the issue as the dueling sides and media look to dispel myths about what's true and what's not.
The same signal responsible for promoting the type of immune responses that cause asthma and allergy can also limit the type of inflammation associated with debilitating diseases like inflammatory bowel disease, arthritis and multiple sclerosis, according to researchers from the University of Pennsylvania School of Veterinary Medicine.
› Verified 4 days ago
| Entity Name | Mgmc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891797148 PECOS PAC ID: 9537073119 Enrollment ID: O20031220000056 |
News Archive
Healthnostics, Inc., a medical and biotechnology analytics company today announced the inclusion of a hospitalist (hospital employed physicians, physician assistants and nurse practitioners) focus for the MedGuardian patient clinical monitoring and risk management system.
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
Advertising on the health care debate, more than $100 million of it spent so far, is offering little understanding on the issue as the dueling sides and media look to dispel myths about what's true and what's not.
The same signal responsible for promoting the type of immune responses that cause asthma and allergy can also limit the type of inflammation associated with debilitating diseases like inflammatory bowel disease, arthritis and multiple sclerosis, according to researchers from the University of Pennsylvania School of Veterinary Medicine.
› Verified 4 days ago
| Entity Name | Emergency Medicine Associates Pa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134117393 PECOS PAC ID: 8022914522 Enrollment ID: O20070919000389 |
News Archive
Healthnostics, Inc., a medical and biotechnology analytics company today announced the inclusion of a hospitalist (hospital employed physicians, physician assistants and nurse practitioners) focus for the MedGuardian patient clinical monitoring and risk management system.
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
Advertising on the health care debate, more than $100 million of it spent so far, is offering little understanding on the issue as the dueling sides and media look to dispel myths about what's true and what's not.
The same signal responsible for promoting the type of immune responses that cause asthma and allergy can also limit the type of inflammation associated with debilitating diseases like inflammatory bowel disease, arthritis and multiple sclerosis, according to researchers from the University of Pennsylvania School of Veterinary Medicine.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vanaja Nandini Alexander, MD 25 Adams Ave Unit 215, Stamford, CT 06902-3786 Ph: (203) 832-0360 | Vanaja Nandini Alexander, MD 3708 5th St S, Arlington, VA 22204-1681 Ph: (703) 403-4672 |
News Archive
Healthnostics, Inc., a medical and biotechnology analytics company today announced the inclusion of a hospitalist (hospital employed physicians, physician assistants and nurse practitioners) focus for the MedGuardian patient clinical monitoring and risk management system.
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
Advertising on the health care debate, more than $100 million of it spent so far, is offering little understanding on the issue as the dueling sides and media look to dispel myths about what's true and what's not.
The same signal responsible for promoting the type of immune responses that cause asthma and allergy can also limit the type of inflammation associated with debilitating diseases like inflammatory bowel disease, arthritis and multiple sclerosis, according to researchers from the University of Pennsylvania School of Veterinary Medicine.
› Verified 4 days ago
Dr. Hiren Gandhi, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3801 Fairfax Dr, Ste#44, Arlington, VA 22203 Phone: 703-522-4780 Fax: 703-527-8695 | |
Sarah A Hesselmann, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1715 N George Mason Dr, Suite 205, Arlington, VA 22205 Phone: 703-522-7300 Fax: 703-522-0495 | |
Emily Elizabeth Pagan, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5275 Lee Hwy Ste 200, Arlington, VA 22207 Phone: 703-717-4090 Fax: 703-717-4091 | |
Dr. Elizabeth Ann Cilenti, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 2445 Army Navy Dr Ste 400, Arlington, VA 22206 Phone: 703-379-8878 Fax: 703-998-6821 | |
Dr. Victoria Saunders, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3401 Columbia Pike Ste 200, Arlington, VA 22204 Phone: 703-717-7545 Fax: 703-271-8585 | |
Dr. Caroline Elise Schulz, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3801 Fairfax Dr Ste 44, Arlington, VA 22203 Phone: 703-522-4780 Fax: 703-527-8695 | |
Rajesh Puri, M.D., FAAP, FACPH Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 2221 N Buchanan St, Suite B., Arlington, VA 22207 Phone: 703-688-2468 Fax: 703-688-2608 |